Welcome! Our laboratory studies the mechanisms underlying complex neurodegenerative diseases, including Alzheimer’s Disease, Parkinson’s Disease and Frontotemporal Lobar Degeneration (FTLD). Our techniques range from cellular neurobiology to population studies and clinical trials. We’re interested in identifying new disease-related biological pathways, evaluating new experimental therapeutics, and developing new disease-specific biomarkers.
News
Apr 02, 2026 - Welcome, Nola!We are thrilled to welcome Nola Ihejirika to the lab! Nola is a Doctoral Student in Brown University's Pathobiology Program.
Nola will be working on synaptic resilience in Alzheimer's disease.
Welcome, Nola!
Dec 06, 2025 - Ted Wilson appointed to named chairTed Wilson named Provost’s Assistant Professor of Neuroimmunology and Brain Science.
Dec 01, 2025 - We’ve moved!The Wilson Lab has moved to Brown University! Contact us if you are interested in collaborating or joining our group of exceptional scientists!
Sep 03, 2025 - Ted and Bella were recently featured in Stanford’s Neuroscience NewsStanford undergrads and local community college students paired with Wu Tsai Neurosciences Institute researchers to find new ways to head off strokes, predict Alzheimer's disease, and more.
Aug 21, 2025 - Our work highlighted by Stanford University’s Knight Initiative for Brain ResilienceParkinson’s comes in many forms. New biomarkers may explain why.
Latest Publications
Ali, M., J. Timsina, Y. Xu, Y. Chen, K. Gong, D. Western, G. Heo, M. Liu, J. Budde, C. Pottier, S. E. Schindler, J. C. Morris, D. M. Holtzman, R. Puerta, A. Cano, M. Boada, M. V. Fernandez, A. Ruiz, M. Aguilar, I. Alvarez, P. Pastor, J. S. Perlmutter, M. C. Campbell, P. T. Kotzbauer, H. S. Oh, E. N. Wilson, Y. L. Guen, C. Knight Alzheimer Disease Research, I. Alzheimer Disease Neuroimaging, A. C. E. A. C. B. Fundacio, Barcelona, C. Stanford Alzheimer Disease Research, C. Global Neurodegeneration Proteomics, R. Tarawneh, T. Wyss-Coray, Y. J. Sung, L. Ibanez and C. Cruchaga (2026). "Large-scale CSF and plasma proteomics reveal immune, synaptic, and extracellular matrix disruptions across neurodegenerative diseases." Neuron. [PubMed]
Shi SM, Tender GS, Xiong J, Buff JK, Park HI, Mendiola JH, Wilson EW, Abu-Remaileh M, Bertozzi CR & Wyss-Coray T "Mucin-binding protein shuttles enable delivery of brain-targeted therapeutics". bioRxiv. (2026). [PubMed]
Do AN, Song S, Ali M, Timsina J, Wang L, Western D, Liu M, Sanford J, Rosende-Roca M, Boada M, Puerta R, Wilson EN, Ruiz A, Pastor P, ADNI, Wyss-Coray T & Cruchaga C “CSF proteomic profiling with amyloid and tau pathology identifies distinctive sex-specific alteration of multiple proteins involved in Alzheimer’s disease” Alzheimer’s & Dementia. 22(1):e71063 (2026). [PubMed]
Winer, JR, Vossler H, Young CB, Smith V, Romero A, Shahid-Besanti M, Abdelnour C, Wilson EN, Anders D, Pacheco Morales A, Andreasson KI, Yutsis MV, Henderson VW, Davidzon GA, Mormino EC, Poston KL “18F-PI-2620 Tau PET is associated with cognitive and motor impairment in Lewy body disease” Brain Communications. 7(1) (2025). [PubMed]
